These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 32107989)

  • 1. B cells targeting therapy in the management of systemic lupus erythematosus.
    Lee WS; Amengual O
    Immunol Med; 2020 Mar; 43(1):16-35. PubMed ID: 32107989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R; Anolik JH
    Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
    Harvey PR; Gordon C
    BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases.
    Samy E; Wax S; Huard B; Hess H; Schneider P
    Int Rev Immunol; 2017 Jan; 36(1):3-19. PubMed ID: 28215100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.
    Vincent FB; Morand EF; Mackay F
    Immunol Cell Biol; 2012 Mar; 90(3):293-303. PubMed ID: 22231653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
    Lenert A; Lenert P
    Drug Des Devel Ther; 2015; 9():333-47. PubMed ID: 25609919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next stop in the treatment of refractory systemic lupus erythematosus: B-cell targeted combined therapy.
    Bela MM; Espinosa G; Cervera R
    Lupus; 2021 Jan; 30(1):134-140. PubMed ID: 33081591
    [No Abstract]   [Full Text] [Related]  

  • 8. Belimumab therapy in systemic lupus erythematosus.
    Zouali M; Uy EA
    BioDrugs; 2013 Jun; 27(3):225-35. PubMed ID: 23568179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus.
    Hui-Yuen JS; Nguyen SC; Askanase AD
    Lupus; 2016 Sep; 25(10):1086-96. PubMed ID: 27497253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress with the use of monoclonal antibodies for the treatment of systemic lupus erythematosus.
    Jordan N; Lutalo PM; D'Cruz DP
    Immunotherapy; 2015; 7(3):255-70. PubMed ID: 25804478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N; D'Cruz DP
    Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New treatments for SLE: cell-depleting and anti-cytokine therapies.
    Anolik JH; Aringer M
    Best Pract Res Clin Rheumatol; 2005 Oct; 19(5):859-78. PubMed ID: 16150407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data.
    Looney RJ
    Drugs; 2010 Mar; 70(5):529-40. PubMed ID: 20297867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B cell alterations during BAFF inhibition with belimumab in SLE.
    Ramsköld D; Parodis I; Lakshmikanth T; Sippl N; Khademi M; Chen Y; Zickert A; Mikeš J; Achour A; Amara K; Piehl F; Brodin P; Gunnarsson I; Malmström V
    EBioMedicine; 2019 Feb; 40():517-527. PubMed ID: 30593436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in therapeutic targets-related study on systemic lupus erythematosus.
    Wang X; Zhang Q; Luo S; Zhang H; Lu Q; Long H
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Nov; 46(11):1267-1275. PubMed ID: 34911862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the BLyS-APRIL signaling pathway in SLE.
    La Cava A
    Clin Immunol; 2013 Sep; 148(3):322-7. PubMed ID: 23269199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-cell activating factor targeted therapy and lupus.
    Boneparth A; Davidson A
    Arthritis Res Ther; 2012; 14 Suppl 4(Suppl 4):S2. PubMed ID: 23281926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus.
    Stohl W
    Expert Opin Ther Targets; 2014 Apr; 18(4):473-89. PubMed ID: 24521424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration.
    Poh YJ; Baptista B; D'Cruz DP
    Expert Rev Clin Immunol; 2017 Oct; 13(10):925-938. PubMed ID: 28847197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus.
    Sthoeger Z; Sharabi A; Mozes E
    J Autoimmun; 2014 Nov; 54():60-71. PubMed ID: 24958634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.